Latest Hotspot

NextCure Reveals Findings from NC410 and Pembrolizumab Phase 1b Trial at ESMO 2024

18 September 2024
3 min read

NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical firm focused on the discovery and development of innovative, top-tier therapies for cancer treatment, has disclosed that clinical findings from the Phase 1b segment of a Phase 1b/2 trial assessing NC410, a LAIR-2 fusion protein, in conjunction with pembrolizumab were presented at ESMO 2024.

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

The clinical trial focusing on ovarian cancer and immune checkpoint inhibitor (ICI) naïve and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) has demonstrated significant clinical activity in these challenging cancer types. The findings were relayed by Dr. Emese Zsiros, M.D., Ph.D., Associate Professor of Oncology and Chair of the Department of Gynecologic Oncology at Roswell Park Comprehensive Cancer Center (ovarian), and Dr. Eric S. Christenson, M.D., Assistant Professor of Oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center (CRC).

"The combinatory therapy of NC410 and pembrolizumab continues to show clinical effectiveness against ovarian cancer as well as MSS/MSI-L CRC, which are particularly resistant to immunotherapy. In both cancer types, study participants who experienced partial response or stable disease showed a durability of response that is meaningful for these groups of patients," stated Dr. Udayan Guha, M.D., Ph.D., Senior Vice President, Clinical and Translational Development at NextCure. "Our team will keep monitoring the participants who are still under study and we anticipate providing an update later in the year."

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

According to the data provided by the Synapse Database, As of September 18, 2024, there are 1 investigational drug for the LAIR2 targets, including 9 indications, 1 R&D institution involved, with related clinical trials reaching 2, and as many as 462 patents.

NC-410 is a fusion protein drug developed by NextCure, Inc. It targets the protein LAIR2 and is being developed for the treatment of various therapeutic areas including neoplasms, digestive system disorders, endocrinology and metabolic disease, respiratory diseases, and urogenital diseases. The active indications for NC-410 include endometrial carcinoma, esophageal carcinoma, lung cancer, metastatic solid tumor, uterine cervical cancer, advanced malignant solid neoplasm, colorectal cancer, ovarian cancer, and stomach cancer.

图形用户界面, 文本, 应用程序

描述已自动生成

Promising Phase 1 Outcomes for Trishula’s TTX-030 in Metastatic Pancreatic Cancer
Latest Hotspot
3 min read
Promising Phase 1 Outcomes for Trishula’s TTX-030 in Metastatic Pancreatic Cancer
18 September 2024
Trishula Therapeutics Shows Promising Phase 1 Results for TTX-030 in Initial Treatment of Metastatic Pancreatic Cancer.
Read →
ImmVira Discusses MVR-T3011 Clinical Data for High-Risk BCG-Failure NMIBC at ESMO 2024
Latest Hotspot
3 min read
ImmVira Discusses MVR-T3011 Clinical Data for High-Risk BCG-Failure NMIBC at ESMO 2024
18 September 2024
ImmVira Presents Clinical Data on Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC at ESMO 2024.
Read →
Antennova Presents New CD73 Inhibitor Data with 89.5% DCR at ESMO 2024
Latest Hotspot
4 min read
Antennova Presents New CD73 Inhibitor Data with 89.5% DCR at ESMO 2024
18 September 2024
Antennova Unveils New Data on CD73 Inhibitor ATN-037, Showcasing an 89.5% DCR, in a Brief Presentation at ESMO Congress 2024.
Read →
GV20 Therapeutics Announces Promising GV20-0251 Phase 1 Results at 2024 ESMO Congress
Latest Hotspot
3 min read
GV20 Therapeutics Announces Promising GV20-0251 Phase 1 Results at 2024 ESMO Congress
18 September 2024
GV20 Therapeutics Shares Encouraging Phase 1 Monotherapy Results for New Checkpoint Inhibitor GV20-0251 at 2024 ESMO Congress.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.